Piper Sandler Reiterates Buy Rating on DexCom, Inc. (DXCM)

Piper Sandler has reiterated its buy rating on DexCom, Inc. (NASDAQ: DXCM) with a price target of $88. This announcement came on June 15, 2026, as DexCom's shares traded around $75.37.

Other Institutional Activity in DexCom

Tudor Investment Corp Et Al significantly increased its holdings in DexCom by 69.1 million shares, ending with 69.2 million shares valued at approximately $63.8 million. BlackRock, Inc. trimmed its position by 884,006 shares, leaving it with about 38.9 million shares worth $2.45 billion. Vanguard Capital Management LLC maintained its stake at 25 million shares valued at $1.57 billion, while State Street Corp slightly reduced its holdings by 158,707 shares to 17.9 million shares, valued at $1.13 billion.

DexCom Stock Snapshot

Shares of DexCom, Inc. (NASDAQ: DXCM) recently traded around $75.37. The company has a market capitalization of approximately $29.08 billion and a P/E ratio of 32.35, with a forward P/E of 24.45. DexCom's stock has seen a 52-week low of $54.11 and a high of $89.98. The company's beta is 1.44, indicating a higher volatility compared to the market. Its 50-day moving average is $65.87, and the 200-day moving average is $67.57.

Recent Earnings

DexCom reported revenue of $4.82 billion, reflecting a 15% growth. The company's net margin stands at 19.31%, with a return on equity of 35.62%. The next earnings report is scheduled for July 29, 2026.

Insider Buying and Selling at DexCom, Inc.

Recent insider transactions at DexCom include planned sales by EVP Jon Coleman, who sold 4,911 shares on June 4, 2026, at an average price of $74.13, and 4,912 shares on June 3, 2026, at $73. Additionally, board members Bridgette Heller, Albert Frederick Osterloh IV, Mark Foletta, and Euan Ashley each purchased shares on May 28, 2026, though the exact price was not disclosed.

Analysts Set New Price Targets

On June 15, 2026, Piper Sandler reiterated its buy rating on DexCom with an $88 price target. TD Cowen maintained a buy rating with a $95 target on June 10, while Mizuho set an $85 target on June 9. Stifel also maintained its buy rating with a $90 target on June 5. Overall, the consensus recommendation is a strong buy, with a mean target price of $84.67 among 24 analysts.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is a healthcare company in the medical devices industry. It focuses on designing and selling continuous glucose monitoring (CGM) systems for diabetes management. Key products include the Dexcom G6 and G7 CGM systems and the Dexcom ONE+ for diabetes treatment decisions. The company serves endocrinologists, physicians, and diabetes educators and employs around 11,000 people under the leadership of CEO Jacob Steven Leach.

Bottom Line

Piper Sandler's reiterated buy rating on DexCom highlights the firm's confidence in the company's growth potential. With a solid market position and a strong product line in continuous glucose monitoring, DexCom remains a noteworthy player in the healthcare sector. Investors should note that 13F filings and analyst ratings are backward-looking and may not reflect current positions or conditions.